Company Evaluations

Solid, well-considered and compelling business strategies are vital to secure investment for innovative life science ventures

Investment in Life Sciences has declined over the last 5 years – at least it has become more difficult to obtain for the majority of early-stage BioTechs and start-up Companies. There are few, new, specialised funds whilst established players are adjusting their respective risk profiles away from early stage or drug discovery projects, towards ‘safer areas’ which hold less systemic risk.

However, fund managers need to increase their assets under management to grow their own businesses and, clearly, need to invest in order to do this. Within Europe in particular, we are now seeing the launch of a number of life science specific funds which, together, suggest a through-to-exit, as long as the investment case is seen to be solid. To this end, investor pitches need to convey strong, convincing, well-reasoned stories.

If you are a University-based research group that wishes to consider setting up a spin-out company to exploit an innovation – or an early-phase BioTech company with early-stage assets who requires funding to progress development – Atebion BDS can provide an independent pre-money Company Valuation and liaise with potential investors as required.

Similarly, we can assist Investment Groups in their investment decision-making by providing commercial assessments of potential companies and their portfolios. Our valuations range from top-line commercial value estimates to a detailed service which includes analyses of the technology vs unmet need, the competition (on-market and in development) & IP strategy, plus advice and guidance on development pathways, investment funding strategy, management structure and commercialisation strategies.

Valuations take many factors into account, including:

  • Major development events
  • The strength of a Management Team
  • Track record of securing investments or grants
  • Strength of IP
  • Probability of Success of development candidates vs Industry standard attrition rates (by therapy area)
  • The competitive nature of the development pipeline in the chosen field
  • The deal making nature of the relevant market – and associated deal values
  • Future market dynamics
  • Comparative companies success in Investment Rounds

Atebion offers VC advice and guidance and can arrange for dedicated consultancy or longer term VC support should you require investment round coordination and/or leadership.

Recent Valuations include:

  • Early-stage BioTech Companies at (i) Lead Optimisation stage & (ii) Pre-clinical stage, with back-up candidates
  • University spin-out companies with innovative platform technologies in drug discovery
    Assessments have included drug candidates across several therapy areas, biologics and technologies.